-
公开(公告)号：KR1020040098746A
公开(公告)日：2004-11-26
申请号：KR1020030030982
申请日：2003-05-15
Applicant: 한국화학연구원
IPC: A61K47/30
CPC classification number: A61K9/0024 , A61K9/1629
Abstract: PURPOSE: Provided is a controlled drug delivery system of a locally implantable agent which controls an initial release speed and duration of drug by adding a biodegradable polymer as a carrier and its monomers to reduce toxicity due to drug-overadministration and other adverse side effects. CONSTITUTION: The controlled drug delivery system of a locally implantable agent is characterized by including or dispersing an effective amount of drug in a mixture of 20-99 wt.% of a biodegradable polymer as a carrier and 1-80 wt.% of its monomers.
Abstract translation: 目的：提供一种局部植入药物的受控药物递送系统，其通过添加可生物降解的聚合物作为载体和其单体来控制药物的初始释放速度和持续时间，以减少由于药物过量给药引起的毒性和其他不良副作用。 构成：本地可植入药物的受控药物递送系统的特征在于将有效量的药物包含或分散在20-99重量％的可生物降解的聚合物作为载体和1-80重量％的单体的混合物中 。
-
公开(公告)号：KR100479637B1
公开(公告)日：2005-03-31
申请号：KR1020020005848
申请日：2002-02-01
Applicant: 한국화학연구원
IPC: A61K9/50
Abstract: 본 발명은 란소프라졸을 함유하는 경구제제, 더욱 자세하게는 란소프라졸이 함유된 코어와 상기 코어의 외층에 전분층, 장용피층, 전분층 및 왁스층을 포함하는 란소프라졸을 함유하는 경구제제 및 이의 제조방법에 관한 것으로서, 본 발명에 따른 경구제제는 위산에 대한 내산성이 우수할 뿐만 아니라 소장 상부에서의 약물 용출성이 높고 신속하며 보관안정성이 우수하여 약효의 저하 없이 장기간 보관 가능하다.
-
公开(公告)号：KR1020040017002A
公开(公告)日：2004-02-26
申请号：KR1020020049074
申请日：2002-08-20
Applicant: 한국화학연구원
IPC: A61K47/00
CPC classification number: A61K9/0004 , A61K9/0014 , A61K31/505 , A61K47/30
Abstract: PURPOSE: Provided is a locally implantable pharmaceutical preparation of anticancer agent containing an osmotic agent. Therefore, its drug release is controlled and its cytotoxicity is increased. CONSTITUTION: A locally implantable pharmaceutical preparation of anticancer agent is characterized in that a pharmaceutical composition consisting of nitrosourea based anticancer agents and biodegradable polymers is added with 1-50 wt.% of an osmotic agent selected from salt, saccharides and saccharide mixtures.
Abstract translation: 目的：提供含有渗透剂的抗癌剂的局部可植入药物制剂。 因此，其药物释放受到控制，其细胞毒性增加。 构成：抗癌剂的局部可植入药物制剂的特征在于，由以亚硝基脲为基础的抗癌剂和可生物降解聚合物组成的药物组合物中加入1-50重量％的选自盐，糖和糖混合物的渗透剂。
-
公开(公告)号：KR100358076B1
公开(公告)日：2002-10-25
申请号：KR1019990033693
申请日：1999-08-16
Applicant: 한국화학연구원
IPC: A61K31/35
Abstract: 본발명은생체이용율을증진시킨경구용이프리플라본제제에관한것으로서, 더욱상세하게는골다공증치료제로사용하는이프리플라본원제제를수용성고분자및 부형제에고체분산시킴과동시에상기약제의결정크기를 10 ㎚∼ 20 ㎛로아주작게분산시킴으로써, 수용성고분자에상기이프리플라본이포접되어종래보다적은약물의투여량과적은횟수로복용하여도소화위장관내의체액에대한용해도와유효혈중농도를증가시키므로약물의과다투여로인한사용상의불편함과위장에대한부담을감소시킬수 있는생체이용율을증진시킨경구용이프리플라본제제에관한것이다.
-
公开(公告)号：KR1020010098419A
公开(公告)日：2001-11-08
申请号：KR1020010014982
申请日：2001-03-22
Applicant: 한국화학연구원
IPC: A61K9/10
CPC classification number: A61K9/0053 , A61K31/496 , A61K47/12 , A61K47/32
Abstract: 본 발명은 생체이용율이 증진된 경구용 이트라코나졸 제제에 관한 것으로서, 더욱 상세하게는 항진균제로 사용하는 이트라코나졸 원제제를 폴리비닐피롤리돈 및 흡수증진제에 고체분산시킴과 동시에 상기 약제의 결정을 무정형화함으로써, 폴리비닐피롤리돈 및 흡수증진제에 이트라코나졸이 포접되어 종래보다 적은 약물의 투여량과 적은 횟수로 복용하여도 소화위장관내의 체액에 대한 용해도와 유효 혈중농도를 증가시켜 생체이용율을 획기적으로 증진시키며 이에 따라 약물의 과다 투여로 인한 사용상의 불편함과 위장에 대한 부담을 감소시키고, 보관중에는 무정형의 이트라코나졸이 결정형 이트라코나졸으로 변환되지 않아 장기보관 안정성을 획기적으로 증진시킨 경구용 이트라코나졸 제제에 관한 것이다.
-
Patent Agency Ranking
公开(公告)号：KR1020040044319A
公开(公告)日：2004-05-28
申请号：KR1020020072825
申请日：2002-11-21
Applicant: 한국화학연구원
IPC: A61K9/00
CPC classification number: A61K9/286 , A61K9/5036 , A61K31/4439
Abstract: PURPOSE: Provided are an oral dosage form of benzimidazole derivative coated with sodium alginate and a preparation method thereof. The manufactured oral preparation has excellent drug release and gastric juice tolerance, a well as high storage stability. CONSTITUTION: An oral dosage form of benzimidazole derivative contains a core including benzimidazole derivatives an active ingredient and at least one of coating layers, such as a starch layer, an enteric-soluble layer, a sodium alginate layer.
Abstract translation: 目的：提供涂覆有藻酸钠的苯并咪唑衍生物的口服剂型及其制备方法。 制备的口服制剂具有优异的药物释放和胃液耐受性，具有高的储存稳定性。 构成：苯并咪唑衍生物的口服剂型含有包括苯并咪唑衍生物的活性成分的核心和淀粉层，肠溶溶性层，藻酸钠层等涂层中的至少一种。
-
公开(公告)号：KR100394075B1
公开(公告)日：2003-08-06
申请号：KR1020010014982
申请日：2001-03-22
Applicant: 한국화학연구원
IPC: A61K9/10
Abstract: 본 발명은 생체이용율이 증진된 경구용 이트라코나졸 제제에 관한 것으로서, 더욱 상세하게는 항진균제로 사용하는 이트라코나졸 원제제를 폴리비닐피롤리돈 및 흡수증진제에 고체분산시킴과 동시에 상기 약제의 결정을 무정형화함으로써, 폴리비닐피롤리돈 및 흡수증진제에 이트라코나졸이 포접되어 종래보다 적은 약물의 투여량과 적은 횟수로 복용하여도 소화위장관내의 체액에 대한 용해도와 유효 혈중농도를 증가시켜 생체이용율을 획기적으로 증진시키며 이에 따라 약물의 과다 투여로 인한 사용상의 불편함과 위장에 대한 부담을 감소시키고, 보관중에는 무정형의 이트라코나졸이 결정형 이트라코나졸으로 변환되지 않아 장기보관 안정성을 획기적으로 증진시킨 경구용 이트라코나졸 제제에 관한 것이다.
-
-
公开(公告)号：KR1020030065825A
公开(公告)日：2003-08-09
申请号：KR1020020005848
申请日：2002-02-01
Applicant: 한국화학연구원
IPC: A61K9/50
CPC classification number: A61K9/5036 , A61K9/2886 , A61K9/5015 , A61K9/5042 , A61K31/4439
Abstract: PURPOSE: A process of preparing an oral formulation containing a starch layer, an enteric coating layer and a wax layer coated on the exterior of a core containing lansoprazole is provided, Therefore, the oral formulation has excellent resistance to gastric acid, is very high in solubility in the vicinity of the small intestine and has excellent storage stability. CONSTITUTION: To produce the oral formulation, starch is coated on the exterior of a core containing lansoprazole to produce a first starch layer. Then, starch is coated on an enteric coating layer to produce a second starch layer and then a wax component is coated on the second starch layer to produce a wax layer. The oral formulation comprises 80 to 300 parts by weight of the first and second starch layer, 3 to 25 parts by weight of the enteric coating layer and 1 to 300 parts by weight of the wax layer, based on the total weight of oral formulation.
Abstract translation: 目的：提供一种制备含有淀粉层，肠溶衣层和涂布在含有兰索拉唑核心的外部的蜡层的口服制剂的方法。因此，口服制剂对胃酸具有优异的抗性，非常高 在小肠附近的溶解性并且具有优异的储存稳定性。 构成：为了生产口服制剂，将淀粉涂覆在含有兰索拉唑的核心的外部以产生第一淀粉层。 然后，将淀粉涂覆在肠溶衣层上以产生第二淀粉层，然后将蜡组分涂覆在第二淀粉层上以产生蜡层。 基于口服制剂的总重量，口服制剂包含80至300重量份的第一和第二淀粉层，3至25重量份的肠溶衣层和1至300重量份的蜡层。
-
公开(公告)号：KR1020020014570A
公开(公告)日：2002-02-25
申请号：KR1020000047918
申请日：2000-08-18
Applicant: 한국화학연구원
IPC: C07D311/76
CPC classification number: A61K9/146 , A61K9/145 , A61K31/352 , A61K47/28
Abstract: PURPOSE: Provided is a process for preparing amorphous ipriflavone having increases bioavailability. When ipriflavone containing amorphous ipriflavone as an active ingredient is formulated and administered orally, its blood concentration easily reaches the effective level with less dose than conventional preparations. CONSTITUTION: The amorphous ipriflavone is manufactured by solid dispersing the mixture of the water soluble polymer solution with the solution containing ipriflavone and absorption enhancer in the water soluble polymer solution by fluidized bed spray drying machine or solid dispersing the mixture of ipriflavone with alginic acid and polyethylene glycol by melting the mixture at 90deg.C. The above water soluble polymer is one or more polymer mixtures selected from polyvinylpyrrolidone, polyvinylalcohol, polyethylene glycol, gum-arabic, dextran, dextrin, gelatin, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, pluronic acid, poloxamer and polysorbate. The above absorption enhancer is one or mixtures of more than two selected from citric acid, alginic acid, ascorbic acid, bile acid, lithocolic acid, cholic acid, deoxycholic 5β-cholanic acid, trihydroxycholane, cholesterol, cholesteryl oleate, cholesteryl palmitate, choleseryl acetate, cholesteryl stearate, salicylic acid, mannitol, xylitol, dextrose, glucose, sucrose, galactose, sorbitol, lactose, fructose, maltose, pentaerythritol, and pentaerythritol tetraacetate.
Abstract translation: 目的：提供增加生物利用度的非晶异黄酮的制备方法。 当配制含有异黄酮异黄酮作为活性成分的异唑酮时，口服给药，其血药浓度容易达到有效水平，剂量比常规制剂低。 构成：通过流化床喷雾干燥机将水溶性聚合物溶液的混合物与含有异黄酮和吸收促进剂的溶液固体分散在水溶性聚合物溶液中或将异黄酮与藻酸和聚乙烯的混合物固体分散在一起制备无定形异黄酮 乙二醇通过将混合物熔化在90℃。 上述水溶性聚合物是选自聚乙烯吡咯烷酮，聚乙烯醇，聚乙二醇，阿拉伯树胶，葡聚糖，糊精，明胶，甲基纤维素，乙基纤维素，羟乙基纤维素，羟丙基纤维素，羧甲基纤维素，普朗尼克酸，泊洛沙姆和 聚山梨酯。 上述吸收增强剂是选自柠檬酸，藻酸，抗坏血酸，胆汁酸，石油酸，胆酸，脱氧胆酸5β-胆酸，三羟基胆甾醇，胆固醇，胆固醇油酸酯，胆固醇基棕榈酸酯，胆固醇酯乙酸酯 ，硬脂酸胆固醇酯，水杨酸，甘露糖醇，木糖醇，葡萄糖，葡萄糖，蔗糖，半乳糖，山梨醇，乳糖，果糖，麦芽糖，季戊四醇和季戊四醇四乙酸酯。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
